{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-047805","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2025-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.739629+00:00","generated_at":"2026-05-20T10:38:23.835552+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Relmada shareholders elect director, ratify auditor, approve 2M share increase to 2021 equity plan","bullets":["Annual meeting held May 23, 2025; 53.6% quorum attained.","John Glasspool elected Class I director (36-month term) with 7.14M for, 2.60M withheld.","Ratification of CBIZ CPAs as auditor for FY2025 approved: 16.44M for, 0.86M against.","Amendment to 2021 Plan approved: share pool increased by 2,000,000 to 9,900,000 total.","Continuing Class II directors: Charles Casamento and Sergio Traversa; Class III: John Glasspool and Paul Kelly."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-047805","json":"https://secwatch.observer/filing/0001213900-25-047805.json","markdown":"https://secwatch.observer/filing/0001213900-25-047805.md","text":"https://secwatch.observer/filing/0001213900-25-047805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025047805/0001213900-25-047805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025047805/ea0243544-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T10:38:23.835552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}